Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aromatase Inhibitors and Weight Loss in Severely Obese Men With Hypogonadism
NCT03490513Phase 4Completed
- Sponsor
- Baylor College of Medicine
- Start
- May 2018
- Primary completion
- Jun 2025
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in hypogonadotropic hypogonadism (HH) comparing Placebo + Weight Loss with Anastrozole + Weight Loss (2 arms). Primary endpoints: Change in Serum Testosterone at 12 months, Percent Change in Muscle Strength at 12 months and 2 more. Started May 2018; status: completed.
02
Drugs
anastrozole
03
Conditions
hypogonadotropic hypogonadism (HH)
Beyond the preview
Go deeper on NCT03490513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03490513.